Related Experiment Video

Updated: Mar 19, 2026

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

23.0K

Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease

Katharina E Rosenbusch1, Arjan Kortholt1

  • 1Department of Cell Biochemistry, University of Groningen, Nijenborgh 7, 9747 AG Groningen, Netherlands.

Parkinson'S Disease
|June 14, 2016
PubMed

Insights

Leucine-Rich Repeat Kinase 2 (LRRK2) mutations are linked to Parkinson's disease (PD). Research is clarifying LRRK2's role in PD progression, focusing on its activation and links to mitochondrial dysfunction and autophagy for therapeutic targets.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Human Leucine-Rich Repeat Kinase 2 (LRRK2) is implicated in familial and idiopathic Parkinson's disease (PD).
  • The precise cellular functions and disease progression mechanisms of LRRK2 remain incompletely understood.
  • LRRK2 is a Roco protein with a kinase domain, involved in complex activation pathways.

Purpose of the Study:

  • To review recent advancements in understanding LRRK2 activation mechanisms.
  • To explore the link between LRRK2-mediated Parkinson's disease and mitochondrial dysfunction/autophagy.
  • To discuss potential therapeutic strategies targeting LRRK2.

Main Methods:

  • Literature review of LRRK2 function, activation, and PD association.
  • Analysis of studies linking LRRK2 to cellular pathways.
  • Discussion of therapeutic targets based on LRRK2 activity.

Main Results:

  • Parkinson's disease mutations in LRRK2 are associated with reduced GTPase and kinase activity.
  • Accumulating evidence suggests LRRK2-mediated PD involves mitochondrial dysfunction and impaired autophagy.
  • Understanding LRRK2 activation is key to identifying therapeutic targets.

Conclusions:

  • Elucidating LRRK2 activation mechanisms is crucial for understanding Parkinson's disease.
  • LRRK2's role in mitochondrial and autophagic pathways offers potential therapeutic avenues.
  • Targeting LRRK2 activity presents a promising strategy for Parkinson's disease treatment.

More Related Videos

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

10.5K
Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

16.2K

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.4K